Nurix Therapeutics Inc. (NRIX)
NRIX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-11-30, https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/0001549595-26-000016-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-11-30.
Profile
| Field | Value |
|---|---|
| Ticker | NRIX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001549595 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $84.0M |
| Net income | -$264.5M |
| Operating income | -$285.7M |
| Net margin | -314.9% |
| Operating margin | -340.2% |
| Revenue growth | +54.0% |
| Cash | $247.0M |
| Total assets | $688.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 19.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Management considered whether there are conditions or events that raise substantial doubt about the Company's ability to continue as a going concern and evaluated the funds necessary to maintain operations." | 10-Q 2026-10-13 |
| Cash and burn | $720.2M cash; operating cash flow $94.8M a quarter. | Report 2026-08-31 |
| Shares outstanding | 109,249,814 (2026-09-30); 76,883,436 a year earlier; 48,503,768 three years earlier. | Cover page 2026-09-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-03-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, San Jose, California, United States | PCAOB Form AP 2026-02-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $4.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-08-31 | $673.1M | $549.8M | $615.6M | $720.2M | No debt tags | $701.9M | 10-Q 2026-10-13 |
| Q2 2026 2026-05-31 | $9.0M | -$89.5M | -$96.6M | $67.7M | No debt tags | $36.8M | 10-Q 2026-07-09 |
| Q1 2026 2026-02-28 | $6.3M | -$87.2M | -$71.9M | $71.2M | No debt tags | $71.8M | 10-Q 2026-04-08 |
| Q4 2025 2025-11-30 | $13.6M | -$78.2M | -$67.8M | $247.0M | No debt tags | $84.0M | 10-K 2026-01-28 |
| Q3 2025 2025-08-31 | $7.9M | -$86.4M | -$57.4M | $78.4M | No debt tags | $83.7M | 10-Q 2026-10-13 |
| Q2 2025 2025-05-31 | $44.1M | -$43.5M | -$63.2M | $84.3M | No debt tags | $88.4M | 10-Q 2026-07-09 |
| Q1 2025 2025-02-28 | $18.5M | -$56.4M | -$61.1M | $75.9M | No debt tags | $56.4M | 10-Q 2026-04-08 |
| Q4 2024 2024-11-30 | $13.3M | -$58.5M | -$48.8M | $110.0M | No debt tags | $54.5M | 10-K 2026-01-28 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-06 |
| Latest annual report | 10-K | 2026-01-28 |
| Latest quarterly / interim | 10-Q | 2026-10-13 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-03-27 |
Source: SEC EDGAR submissions feed, 567 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.2% |
| 1 month | -30.0% |
| 3 months | -43.1% |
| Year to date | -18.4% |
| 1 year | +24.5% |
| From 52-week high | -44.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ANIP | ANI Pharmaceuticals Inc. | $70.89 | -0.77% | $1.6B |
| RARE | Ultragenyx Pharmaceutical Inc. | $15.90 | -1.12% | $1.6B |
| SRPT | Sarepta Therapeutics Inc. Common Stock (DE) | $15.13 | -5.85% | $1.6B |
| KLRA | Kailera Therapeutics Inc. | $12.57 | -5.28% | $1.6B |
| ADRX | ADARx Pharmaceuticals Inc. | $14.00 | -1.41% | $1.6B |
| PGEN | Precigen Inc. | $4.30 | -5.29% | $1.5B |
| QURE | uniQure N.V. | $21.88 | -8.11% | $1.5B |
| SLS | SELLAS Life Sciences Group Inc. | $7.47 | -4.96% | $1.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier